Abstract
Down syndrome is an intellectual disability requiring periodic monitoring of cognition given the near universal presence of Alzheimer’s Disease related neuropathology and high rates of dementia in middle adulthood. We review current approaches to detecting decline in this population, including informant-based measures, dementia screening tools, and neuroimaging techniques. The challenges for detecting decline in this group are discussed, including the need to take into account premorbid cognitive function as well as medical comorbidity.
Keywords: Alzheimer’s disease, assessment, decline, dementia, down syndrome, neuropsychological, sleep.
Current Alzheimer Research
Title:Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Volume: 13 Issue: 1
Author(s): Marwan Sabbagh and Jamie Edgin
Affiliation:
Keywords: Alzheimer’s disease, assessment, decline, dementia, down syndrome, neuropsychological, sleep.
Abstract: Down syndrome is an intellectual disability requiring periodic monitoring of cognition given the near universal presence of Alzheimer’s Disease related neuropathology and high rates of dementia in middle adulthood. We review current approaches to detecting decline in this population, including informant-based measures, dementia screening tools, and neuroimaging techniques. The challenges for detecting decline in this group are discussed, including the need to take into account premorbid cognitive function as well as medical comorbidity.
Export Options
About this article
Cite this article as:
Sabbagh Marwan and Edgin Jamie, Clinical Assessment of Cognitive Decline in Adults with Down Syndrome, Current Alzheimer Research 2016; 13 (1) . https://dx.doi.org/10.2174/1567205012666150921095724
DOI https://dx.doi.org/10.2174/1567205012666150921095724 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?
Current Alzheimer Research How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Integration of Cognitive Tests and Resting State fMRI for the Individual Identification of Mild Cognitive Impairment
Current Alzheimer Research The Role of PGC-1α in the Pathogenesis of Neurodegenerative Disorders
Current Drug Targets Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Molecular Imaging in the Default Mode Network
Current Molecular Imaging (Discontinued) Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Current Pharmaceutical Design Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research